T1	Participants 115 124	melanoma.
T2	Participants 134 315	Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter, randomized trials, conducted by the Eastern Cooperative Oncology Group and the Intergroup
T3	Participants 697 740	patients in E1684, E1690, E1694, and E2696.
T4	Participants 819 842	713 patients randomized
T5	Participants 1732 1773	patients with high-risk resected melanoma
